Genentech, a member of the Roche Group RHHBY,
today announced early results from a pivotal Phase II study, IMvigor
210, of the investigational cancer immunotherapy atezolizumab
(anti-PDL1; MPDL3280A) in people with locally advanced or metastatic
urothelial carcinoma (mUC). The study showed that atezolizumab shrank
tumors (objective response rate, ORR) in 27 percent of people with mUC
whose disease had medium and high levels of PD-L1 expression and
worsened after initial treatment. Ninety-two percent of people who
responded to atezolizumab continued to respond when the results were
assessed. Median duration of response was not yet reached. Adverse
events were consistent with those observed in previous studies.
"These results may represent
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in